Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, August 7, 2026 at 1:40 AM GMT+3 3 min read

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary - Moby

Strategic Transformation and Portfolio Scaling

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

The acquisition of XOMA Royalty, the largest in Ligand's history, adds over 120 assets and nearly doubles the late-stage clinical pipeline while extending cash flow duration through 2040.
Management attributes the 32% year-over-year royalty revenue growth to broad-based performance across Filspari, Ohtuvayre, and Zelsuvmi, validating the compounding nature of the royalty aggregation model.
The $700 million zero-coupon convertible offering was executed to maintain financial capacity for decisive action in a highly active business development pipeline.
Operational efficiency has improved significantly since 2022, with royalty revenue increasing from $73 million to an expected $225 million-$250 million in 2026 while cash operating expenses were halved.
The business model is designed for resilience against binary clinical risks by maintaining a diversified portfolio where no single product success is required for overall growth.
Management emphasizes a disciplined capital allocation philosophy, focusing on high-quality royalty opportunities with rigorous underwriting led by a lean investment team.

Growth Outlook and Catalyst Cadence

Ligand is entering its most catalyst-rich period, with up to 7 pivotal trial readouts and multiple potential FDA approvals expected over the next 18 months.
The XOMA acquisition is expected to be immediately accretive, contributing approximately $0.50 to adjusted EPS in the second half of 2026 and $1.50 in 2027.
Management expects to utilize over $110 million in Section 174 tax credits and net operating losses over the next 3 to 5 years to drive significant U.S. cash tax savings.
Updated 2026 adjusted EPS guidance of $9.00 to $9.50 reflects incremental earnings from the convertible note proceeds and recent share repurchases.
The company plans to present an updated 5-year outlook at its December Investor Day to reflect the higher growth profile following the XOMA integration.

Financial Adjustments and Risk Factors

A $12 million one-time R&D charge was recorded for the Orchestra Bio investment, which is treated as an expense under GAAP despite being viewed economically as a royalty investment.
XOMA's annual operating expenses are expected to be reduced from $30 million to less than $5 million by eliminating duplicative public company infrastructure.
The portfolio includes $2.3 billion in potential milestone opportunities, though management notes that accounting for financial royalty assets may result in some milestones reducing asset carrying value rather than being recognized as revenue.
Ligand holds a 25% interest in potential net proceeds from the Janssen Tremfya litigation with no obligation to fund costs or downside financial exposure.

Q&A Session Insights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Post-acquisition surprises and early-stage asset potential

Management noted positive developments in assets originally valued at zero during the triage underwriting process.
Ligand is identifying early-to-mid-stage assets where small investments (approximately $2 million to $3 million) could validate clinical proof-of-concept and make them licensable.

Future deal sizing and market competition

Despite the larger balance sheet, Ligand will continue to focus on the sub-$100 million deal market, typically targeting investments between $25 million and $75 million.
Management believes the market for development-stage royalty financing remains underserved, with royalty capital representing less than 5% of biopharmaceutical development funding.

Impact of Mirum's PSC regulatory delay

Management expressed disappointment regarding the FDA's recommendation for a Phase 3 trial for volixibat in PSC but noted the partner received breakthrough therapy designation after the meeting.
The timeline for submission has shifted to the first half of 2027., though management maintains conviction in the asset's long-term potential.